{"id":"NCT00446043","sponsor":"Galderma R&D","briefTitle":"Long-term Study of Efficacy/Safety of Adapalene/Benzoyl Peroxide Topical Gel in Acne Vulgaris Subjects","officialTitle":"A Long-term Safety and Efficacy Study of a Fixed Combination of Adapalene 0.1% and Benzoyl Peroxide 2.5% (Adapalene and Benzoyl Peroxide Topical Gel) Gel in Subjects With Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-02-17","primaryCompletion":"2005-05-23","completion":"2005-05-23","firstPosted":"2007-03-12","resultsPosted":"2023-07-11","lastUpdate":"2023-07-11"},"enrollment":452,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"Adapalene/Benzoyl Peroxide","otherNames":[]}],"arms":[{"label":"Adapalene/Benzoyl Peroxide","type":"EXPERIMENTAL"}],"summary":"This was a multi-center, open-label, non-comparative study that evaluated the long-term safety and efficacy profile of Adapalene/Benzoyl Peroxide Gel.\n\nSubjects were evaluated at Baseline, Weeks 1 and 2, and Months 1, 2, 4, 6, 8, 10, and 12.\n\nSafety was evaluated by spontaneous reports of Adverse Events (AEs), the Local Tolerability Assessment (Erythema, Scaling, Dryness, and Stinging/Burning), routine laboratory testing (hematology, blood chemistry, and urinalysis), and monitoring of suspected sensitizations. Efficacy was evaluated by analysis of Percent Change from Baseline in Inflammatory, Noninflammatory, and Total Lesion Counts, and by the Subject's Assessment of Acne.","primaryOutcome":{"measure":"Percent Change From Baseline in Inflammatory, Noninflammatory and Total Lesion Count at Month 12 LOCF","timeFrame":"Baseline, Month 12 LOCF","effectByArm":[{"arm":"Adapalene/Benzoyl Peroxide","deltaMin":-59.7,"sd":34.268}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["12963896"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":452},"commonTop":["Dry Skin","Application Site Burning","Nasopharyngitis","Upper Respiratory Tract Infection","Erythema"]}}